PPA
NVLN

Parametric Portfolio Associates’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Parametric Portfolio Associates’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-20,236
Closed -$74K – 3995
2018
Q2 		$74K Sell
20,236
-10,065
-33% -$40.4K ﹤0.01% 3830
2018
Q1 		$106K Buy
30,301
+15,264
+102% +$64.7K ﹤0.01% 3851
2017
Q4 		$47K Buy
+15,037
New +$72.3K ﹤0.01% 3874

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Parametric Portfolio Associates's NVLN Position: Q3 2018 in Review

Parametric Portfolio Associates sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2018, closing a stake of 20,236 shares — an estimated $74K sold.

Parametric Portfolio Associates first reported a position in NVLN in Q4 2017 and held it in 3 quarters. The position peaked at $106K in Q1 2018. 49 funds tracked by Wall St. Rank hold NVLN as of Q3 2018.

  • Parametric Portfolio Associates reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2018 after selling out during the quarter.
  • Parametric Portfolio Associates sold 20,236 Novelion Therapeutics Inc. Common Shares shares in Q3 2018, an estimated $74K.
  • Parametric Portfolio Associates first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 3 quarters.
  • Parametric Portfolio Associates's Novelion Therapeutics Inc. Common Shares position peaked at $106K in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2018.

Based on Parametric Portfolio Associates's 13F filing for Q3 2018, filed 13 Nov 2018.